WWA
TRDA icon

WCG Wealth Advisors’s Entrada Therapeutics TRDA Stock Holding History

WCG Wealth Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,830
Closed -$261K – 344
2025
Q1 		$261K Buy
28,830
+4,800
+20% +$59.8K 0.02% 270
2024
Q4 		$415K Buy
24,030
+1,406
+6% +$25.5K 0.03% 277
2024
Q3 		$362K Buy
+22,624
New +$356K 0.02% 292

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

WCG Wealth Advisors's TRDA Position: Q2 2025 in Review

WCG Wealth Advisors sold out of Entrada Therapeutics (TRDA) in Q2 2025, closing a stake of 28,830 shares — an estimated $261K sold.

WCG Wealth Advisors first reported a position in TRDA in Q3 2024 and held it in 3 quarters. The position peaked at $415K in Q4 2024. 107 funds tracked by Wall St. Rank hold TRDA as of Q2 2025.

  • WCG Wealth Advisors reported no remaining Entrada Therapeutics position as of Q2 2025 after selling out during the quarter.
  • WCG Wealth Advisors sold 28,830 Entrada Therapeutics shares in Q2 2025, an estimated $261K.
  • WCG Wealth Advisors first reported a position in Entrada Therapeutics in Q3 2024 and held it in 3 quarters.
  • WCG Wealth Advisors's Entrada Therapeutics position peaked at $415K in Q4 2024.
  • 107 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2025.

Based on WCG Wealth Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.